1. The Role of Neutrophil Elastase Inhibitors in Lung Diseases
Eva Polverino, MD, PhD, Edmundo Rosales-Mayor, MD, Glenn E. Dale, PhD, Klaus Dembowsky, MD, PhD, Antoni Torres, MD, PhD 
CHEST 
Volume 152, Issue 2, Pages (August 2017)
DOI: /j.chest
Copyright © 2017 American College of Chest Physicians Terms and Conditions

2. Figure 1
Innate immune defense. α1-AT = alpha1 antitrypsin; MMP = matrix metalloproteinase; NE = neutrophil elastase; SLPI = secretory leukocyte protease inhibitor.
CHEST  , DOI: ( /j.chest )
Copyright © 2017 American College of Chest Physicians Terms and Conditions

3. Figure 2
Ratio and 90% CI of AZD9668 to placebo for changes in sputum inflammatory biomarkers. Compared with placebo, AZD9668 was associated with reductions in all sputum biomarkers (TNF-α, IL-6, IL-8, IL-1β, RANTES, MCP-1) except LTB4. Changes in IL-6 and RANTES were statistically significant. There were no changes in blood inflammatory biomarkers. LTB4 = leukotriene B4; MCP-1 = monocyte chemoattractant protein-1; RANTES = regulated on activation, normal T-cell expressed and secreted; TNF = tumor necrosis factor.
(Adapted with permission from Elborn et al.57)
CHEST  , DOI: ( /j.chest )
Copyright © 2017 American College of Chest Physicians Terms and Conditions